|
|
Volumn 22, Issue 9, 2004, Pages 1061-
|
|
EU to review rare disease drugs market exclusivity
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AGALSIDASE ALFA;
AGALSIDASE BETA;
ORPHAN DRUG;
BIOTECHNOLOGY;
DRUG LEGISLATION;
DRUG MARKETING;
DRUG RESEARCH;
EUROPEAN UNION;
FABRY DISEASE;
FINANCIAL MANAGEMENT;
HUMAN;
NOTE;
PRIORITY JOURNAL;
PROFIT;
RARE DISEASE;
UTILIZATION REVIEW;
DRUG THERAPY;
EUROPEAN UNION;
GOVERNMENT REGULATION;
LEGISLATION, DRUG;
ORPHAN DRUG PRODUCTION;
OWNERSHIP;
PATENTS;
RARE DISEASES;
|
|
EID: 19244365508
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0904-1061 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|